ATE105859T1 - Proteolytisches enzym, spezifisch für menschlichen immunmangel-virus, verfahren zu seiner herstellung und renaturierung. - Google Patents

Proteolytisches enzym, spezifisch für menschlichen immunmangel-virus, verfahren zu seiner herstellung und renaturierung.

Info

Publication number
ATE105859T1
ATE105859T1 AT88905335T AT88905335T ATE105859T1 AT E105859 T1 ATE105859 T1 AT E105859T1 AT 88905335 T AT88905335 T AT 88905335T AT 88905335 T AT88905335 T AT 88905335T AT E105859 T1 ATE105859 T1 AT E105859T1
Authority
AT
Austria
Prior art keywords
hiv
renaturation
production
proteolytic enzyme
immune deficiency
Prior art date
Application number
AT88905335T
Other languages
English (en)
Inventor
Stephen Oroszlan
Terry D Copeland
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE105859T1 publication Critical patent/ATE105859T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT88905335T 1987-06-01 1988-06-01 Proteolytisches enzym, spezifisch für menschlichen immunmangel-virus, verfahren zu seiner herstellung und renaturierung. ATE105859T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/057,183 US5252477A (en) 1987-06-01 1987-06-01 Human immunodeficiency virus specific proteolytic enzyme and a method for its synthesis and renaturation

Publications (1)

Publication Number Publication Date
ATE105859T1 true ATE105859T1 (de) 1994-06-15

Family

ID=22009015

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88905335T ATE105859T1 (de) 1987-06-01 1988-06-01 Proteolytisches enzym, spezifisch für menschlichen immunmangel-virus, verfahren zu seiner herstellung und renaturierung.

Country Status (10)

Country Link
US (2) US5252477A (de)
EP (1) EP0316429B1 (de)
JP (1) JPH02500408A (de)
KR (1) KR890701738A (de)
AT (1) ATE105859T1 (de)
AU (1) AU630590B2 (de)
DE (1) DE3889625T2 (de)
DK (1) DK41289A (de)
FI (1) FI890459A7 (de)
WO (1) WO1988009815A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252477A (en) * 1987-06-01 1993-10-12 The United States Of America As Represented By The United States Department Of Health And Human Services Human immunodeficiency virus specific proteolytic enzyme and a method for its synthesis and renaturation
US5637488A (en) * 1987-06-01 1997-06-10 The United States Of America As Represented By The Department Of Health And Human Services HIV protease gene and method for its expression
CA1340748C (en) * 1988-07-13 1999-09-14 Stephen Oroszlan Synthetic hiv protease gene and method for its expression
US5866123A (en) * 1990-04-13 1999-02-02 Research Development Foundation Gene encoding cationic amino acid transporter protein
US5147369A (en) * 1991-07-01 1992-09-15 Wagner Michael A Forceps and method for nuclear fragment removal
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
MXPA93002392A (es) 1992-03-11 2005-02-04 Narhex Ltd Derivados amino de hidrocarburos-oxo e hidroxi-substituidos.
JPH07504654A (ja) * 1992-03-11 1995-05-25 ナルヘックス　リミテッド オキソ及びヒドロキシ置換炭化水素のアミン誘導体
US6071895A (en) * 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
US5888992A (en) * 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
US5872210A (en) * 1995-10-05 1999-02-16 The United States Of America As Represented By The Department Of Health And Human Services Transframe peptide inhibitor of viral protease
EP0909322B1 (de) 1996-04-30 2005-11-16 Twinstrand Therapeutics Inc. Antivirale variante von ricin-proteinen
US6531125B1 (en) 1999-03-02 2003-03-11 Twinstrand Therapeutics Inc. Antiviral ricin-like proteins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252477A (en) * 1987-06-01 1993-10-12 The United States Of America As Represented By The United States Department Of Health And Human Services Human immunodeficiency virus specific proteolytic enzyme and a method for its synthesis and renaturation

Also Published As

Publication number Publication date
DK41289D0 (da) 1989-01-30
FI890459L (fi) 1989-01-31
DE3889625D1 (de) 1994-06-23
DK41289A (da) 1989-01-30
FI890459A0 (fi) 1989-01-31
FI890459A7 (fi) 1989-01-31
JPH02500408A (ja) 1990-02-15
AU630590B2 (en) 1992-11-05
EP0316429B1 (de) 1994-05-18
AU1805188A (en) 1989-01-04
KR890701738A (ko) 1989-12-21
DE3889625T2 (de) 1994-09-29
EP0316429A1 (de) 1989-05-24
EP0316429A4 (en) 1991-05-22
WO1988009815A1 (en) 1988-12-15
US5252477A (en) 1993-10-12
US5354683A (en) 1994-10-11

Similar Documents

Publication Publication Date Title
ATE105859T1 (de) Proteolytisches enzym, spezifisch für menschlichen immunmangel-virus, verfahren zu seiner herstellung und renaturierung.
ATE117019T1 (de) Neue hyperthermostabile alpha - amylase.
JPS6427471A (en) Novel enzyme and production of protein gelatinized product using said enzyme
DE69632630D1 (de) Enzym mit aminopeptidaseactivität
DE69942160D1 (de) Verfahren zur Herstellung von L-Aminosäure
ATE71407T1 (de) Verfahren zur herstellung von peroxydase.
ATE130031T1 (de) Verwendungen viraler enzyme.
ATE80657T1 (de) Mischungen von alpha-amylase zur verfluessigung von staerke.
DE68929115D1 (de) Verfahren zur Herstellung von menschlichem Serumalbumin in Hefe
DE69717629D1 (de) Verfahren zur produktion von polypeptiden
ATE81673T1 (de) Verfahren zur beseitigung von nendaminos|ureresten aus eukaryotpolypeptidanlagen und so erzeugte polypeptide.
ATE212059T1 (de) Methoden zur identifizierung heterofunktionaler fusionsproteine
DE3855375D1 (de) Proteolytische enzyme
ATE5314T1 (de) Pharmakologisch aktive peptide und deren zusammensetzungen.
ATE109796T1 (de) Gewebeinhibitor für metalloproteasen (timp-2).
GB1459807A (en) Process for the production of 7-d-a-amino-phenyl-acetamido-3- desacetoxy-cephalosporanic acid
HUP9801439A2 (hu) Béta-D-Galakotpiranozil-D-xilózok alkalmazása bél laktáz kimutatására alkalmas készítmények és oldatok előállításánál, valamint eljárás a vegyületek előállítására
ATE103989T1 (de) Monoklonale antikoerper gegen e7-protein des humanen papillomvirus typ 16, verfahren zu ihrer herstellung sowie ihre verwendung.
KR890008166A (ko) 융합 단백질의 선택적 분해 방법
ATE95188T1 (de) Zellulaere amphipatische proteine in aggregierten formen und verfahren zur herstellung und reinigung diese proteine.
ATE69265T1 (de) Peroxidase und verfahren zu deren herstellung.
ATE69034T1 (de) Verfahren zur herstellung von polychlorophosphazen.
Dean THE EXTRACELLULAR PROTEOLYTIC ENZYMES OF LAGENIDIUM GIGANTEUM.
Debanne et al. Antigenic compositions of enzyme-containing preparations of Bacillus subtilis origins
GB1487690A (en) Production of peptidase

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee